Current role of antibody therapy in patients with metastatic colorectal cancer

被引：40

作者：

Pfeiffer, P. ^{[1
]}

Qvortrup, C. ^{[1
]}

Eriksen, J. G. ^{[1
]}

机构：

[1] Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark

来源：

ONCOGENE | 2007年 / 26卷 / 25期

关键词：

metastatic colorectal cancer; antibodies; bevacizumab; cetuximab; panitumumab;

D O I：

10.1038/sj.onc.1210377

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

In less than 10 years, the number and importance of nonsurgical treatment modalities in patients with colorectal cancer (CRC) have increased dramatically, both in the adjuvant and the advanced settings. However, despite the improvement of cytotoxic therapy in CRC, many patients still develop progressive disease and unfortunately in patients with disease resistant to 5-fluorouracil/folinic acid, irinotecan and oxaliplatin, no effective cytotoxic therapy is known. The rapidly expanding knowledge in tumor biology has encouraged optimism for the possibility to find and target tumor-specific mechanisms and thereby increase both efficacy and tolerance. A great number of 'targeted drugs' are being tested in clinical trials and some of these new drugs, like bevacizumab, cetuximab and panitumumab, are available for routine use in health care. These new targeted drugs will expand the therapeutic arsenal in CRC to a great extent, but they will also add to the complexity of treatment of CRC. In this review, we summarize the current status of antibody therapy in patients with CRC.

引用

页码：3661 / 3678

页数：18

共 148 条

[41]

Giantonio BJ, 2005, J CLIN ONCOL, V23, p1S

[42]

GIANTONIO BJ, 2006, J CLIN ONCOL, V24

[43] Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer [J].

Gibson, Tara Beers ;

Ranganathan, Aarati ;

Grothey, Axel .

CLINICAL COLORECTAL CANCER, 2006, 6 (01) :29-31

[44]

GLIMELIUS B, 2005, EUR J CANC S, V3

[45] A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].

Goldberg, RM ;

Sargent, DJ ;

Morton, RF ;

Fuchs, CS ;

Ramanathan, RK ;

Williamson, SK ;

Findlay, BP ;

Pitot, HC ;

Alberts, SR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30

[46] Influence of storage temperature and high-temperature antigen retrieval buffers on results of immunohistochemical staining in sections stored for long periods [J].

Grabau, DA ;

Nielsen, O ;

Hansen, S ;

Nielsen, MM ;

Laenkholm, AV ;

Knoop, A ;

Pfeiffer, P .

APPLIED IMMUNOHISTOCHEMISTRY, 1998, 6 (04) :209-213

[47] Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment [J].

Grothey, A ;

Sargent, D ;

Goldberg, RM ;

Schmoll, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1209-1214

[48] Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [J].

Grothey, A ;

Sargent, D .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9441-9442

[49]

GROTHEY A, 2003, EUR J CANC, V90

[50] Neoadjuvant therapy with bevacizumab [J].

Gruenberger, T ;

Gruenberger, B ;

Scheithauer, W .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2592-2593

← 1 2 3 4 5 6 7 8 9 10 →